Table 1 Details are provided for patients with primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and autoimmune hepatitis (AIH).
From: Systemic PCSK9 elevation characterises autoimmune liver disease across sexes
Characteristics | PSC | PBC | AIH |
|---|---|---|---|
Males / Females | 31 / 26*** ** | 2 / 31*** | 1 / 9** |
Age (years) | 46 (18–76)**,*** | 61 (31–80)*** | 62 (24–80)** |
BMI (kg/m2) | 23.0 (16.3–31.8)40 ** | 27.4 (20.2–38.8)32 ** | 23.9 (21.3–35.0) |
AST (U/l) | 36 (15–177) | 27 (20–132) | 28 (19–33) |
ALT (U/l) | 35 (5–205)* * | 20 (11–113)* | 18 (9–59)* |
GGT (U/l) | 57 (10–1700)** | 42 (11 -1361)* | 19 (12–116)**,* |
AP (U/l) | 140 (35–587)** | 106 (60–1652) | 80 (53–104)** |
Bilirubin (mg/dl) | 0.7 (0.2–21.3) | 0.5 (0.2–9.9) | 0.5 (0.2–1.2) |
Bilirubin direct (mg/dl) | 0.3 (0.1–2.5)21 | 0.2 (0.1–7.3)30 | 0.3 (0.1–0.4)8 |
Bilirubin indirect (mg/dl) | 0.5 (0.1–2.8)21 | 0.3 (0.1–2.6)30 | 0.3 (0.1–0.8)8 |
LDL (mg/dl) | 121 (50–183)21 | 110 (28–265)28 | 135 (103–163)8 |
Cholesterol (mg/dl) | 200 (131–288)21 | 201 (66–359)28 | 207 (170–229)8 |
Fibroscan | 1 (0–4)46 | 1 (0–4) | 1 (0–4) |
MELD score | 6 (5–20)43 | 6 (5–28)30 | 7 (6–11) |
Diabetes yes/no/n.d | 0/5/13 | 5/23/5 | 0/8/2 |
Cardiovascular disease yes/no/n.d. | 1/4/13 | 3/25/5 | 1/7/2 |
Hypertension yes/no/n.d | 1/4/13 | 5/25/3 | 2/6/2 |
Ursodeoxycholic acid yes/no/n.d. | 49/2/6 | 31/0/2 | 0/10/0 |
Immunsuppressive therapy yes/no/n.d | 11/40/6 | 1/32/0 | 6/4/0 |
Mayo PSC Risk score high/intermediate/low/n.d. | 2/6/19/30 | n.d. | n.d. |
Decompensation during the disease course yes/no/n.d. | 5/23/29 | 6/27/0 | 0/10/0 |
Liver transplantation yes/no/n.d. | 6/22/29 | 3/30/0 | 0/10/0 |
